Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 14/20 | 0.84 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136318 | 0.91 | PIM1 (1.00) | PIM1DYRK1AKCNH2 | |
| SCHEMBL102854 | 0.91 | PIM1 (1.00) | PIM1DYRK1AKCNH2 | |
| SCHEMBL18356752 | 0.90 | PIM1 (0.84) | PIM1DYRK1AKCNH2 | |
| SCHEMBL3864352 | 0.88 | PIM1 (0.71) | PIM1DYRK1AKCNH2 | |
| SCHEMBL13867312 | 0.88 | PIM1 (0.64) | PIM1DYRK1AKCNH2 | |
| SCHEMBL13867132 | 0.87 | PIM1 (0.63) | PIM1DYRK1A | |
| SCHEMBL13867505 | 0.86 | PIM1 (0.83) | PIM1DYRK1AKCNH2 | |
| SCHEMBL13867544 | 0.85 | PIM1 (0.72) | PIM1DYRK1AKCNH2 | |
| SCHEMBL13867366 | 0.84 | PIM1 (0.60) | PIM1DYRK1AKCNH2 | |
| SCHEMBL31541600 | 0.84 | DYRK1A (0.81) | PIM1DYRK1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3812387-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3409278-B1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-2734205-B1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2018-03-21 | — | — | EP | disclosed |